Page 11 - Material Command News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Q3 2023 Product sales grew 20% to $7.8M versus $6.5M in Q3 2022. Q3 2023 Total revenue was approximately $8.8M. The pivotal STAR-T trial remains blinded with database lock nearing and initial data analysis completion expected before year-end.PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorptio

PRINCETON, N.J., Oct. 05, 2023 -- CytoSorbents Corporation , a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification,...

PRINCETON, N.J., Oct. 05, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood

PRINCETON, N.J., Sept. 19, 2023 -- CytoSorbents Corporation , a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly...

Read trending news, stories and press releases from PMN Wire News about Canadian and international businesses.